Cord Blood America Revenue and Competitors

Location

$18M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Cord Blood America's estimated annual revenue is currently $3.5M per year.(i)
  • Cord Blood America's estimated revenue per employee is $269,231
  • Cord Blood America's total funding is $18M.

Employee Data

  • Cord Blood America has 13 Employees.(i)
  • Cord Blood America grew their employee count by -13% last year.

Cord Blood America's People

NameTitleEmail/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$32.4M2096%N/AN/A
#2
$31.5M2031%N/AN/A
Add Company

What Is Cord Blood America?

Cord Partners\' is a stem cell preservation group who believes that providing quality cord blood banking services all parents can afford is essential to securing every family\'s future health. Our commitment to affordability, education, and easy enrollment gives everyone the opportunity to save their newborn\'s umbilical cord blood. We have created a seamless process that makes saving your family\'s cord blood easy, without distracting from the miracle of birth.

keywords:N/A

$18M

Total Funding

13

Number of Employees

$3.5M

Revenue (est)

-13%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Cord Blood America News

2022-04-20 - Umbilical Cord Blood Banking Market Size, Scope And ...

ViaCord Inc., CBR Systems Vita 34 AG, Cord Blood America China Cord Blood Corporation, Cryo-Save AG, Cryo-Cell International Cordlife Group Ltd.

2022-04-19 - Umbilical Cord Blood Banking Market Analysis With Inputs ...

... Current Key Players, Forecast by 2028: CBR Systems, ViaCord, China Cord Blood Corporation, Cord Blood America, Cryo-Cell International.

2022-04-17 - Global Stem Cell/Cord Blood Banking Market Outlook Report ...

Cord Blood America Inc. Stem Cyte; Aldagen; Arteriocyte; Brainstorm Cell Therapeutics. For more information about this report visit https://www.

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$1.4M1318%N/A
#2
$3.1M16N/AN/A
#3
N/A17-11%$4.9M
#4
$3.6M18N/AN/A
#5
$3.1M186%N/A